[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355522-105":59,"doc-detail-355522-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","ablation-of-prostaglandin-e2-signalling-through-dual-receptor-knockout-in-car-t-cells-enhances-therapeutic-efficacy-in-solid-tumours","Ablation of prostaglandin E2 signalling through dual receptor knockout in CAR T cells enhances therapeutic efficacy in solid tumours","","Efficacy of chimeric antigen receptor (CAR) T cell therapy in solid cancers is constrained by immunosuppression within the tumour microenvironment. Prostaglandin E2 (PGE2) is a local mediator that inhibits T-cell function. The study tests whether targeted elimination of PGE2 signalling in CAR T cells increases activity in PGE2-rich tumours. CRISPR–Cas9 creates EP2 and EP4 double-knockout CAR T cells, which expand with PGE2 and control multiple in vivo xenograft models, with improved effects using patient-derived PDAC, CRC, and NET samples.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/ablation-of-prostaglandin-e2-signalling-through-dual-receptor-knockout-in-car-t-cells-enhances-therapeutic-efficacy-in-solid-tumours/355522/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/ablation-of-prostaglandin-e2-signalling-through-dual-receptor-knockout-in-car-t-cells-enhances-therapeutic-efficacy-in-solid-tumours/355522.png","ImageObject",300,407,{"name":92,"@type":93},"Jordan Avery","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why target prostaglandin E2 signalling in CAR T cells for solid tumours?","Question",{"text":113,"@type":114},"PGE2 is highlighted as a key factor locally inhibiting T-cell function, contributing to immunosuppression in the tumour microenvironment.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were the CAR T cells modified in this study?",{"text":118,"@type":114},"Researchers generated knockout CAR T cells double deficient for the PGE2 receptors EP2 and EP4 using CRISPR–Cas9 engineering (EP2−/−EP4−/−).",{"name":120,"@type":111,"acceptedAnswer":121},"What evidence supports enhanced therapeutic efficacy?",{"text":122,"@type":114},"The modified CAR T cells expanded in the presence of PGE2 and effectively controlled syngeneic and human xenograft tumour models in vivo, with improved activity also observed in patient-derived PDAC, CRC, and NET tumour samples.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},355522,1790182399,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},1099523882367,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","nature biomedical engineering  \nArticle [https://doi.org/10.1038/s41551-025-01610-6](https://doi.org/10.1038/s41551-025-01610-6)  \nAblation of prostaglandin E2 signalling through dual receptor knockout inCART cells enhances therapeutic efficacy in solid tumours  \nReceived: 19 March 2024  \nAccepted: 18 December 2025  \n\n| Published online: 11 February 2026 |\n| --- |\n|  Check for updates |\n\nJanina Dörr 1,15, Lisa Gregor 1,15, Sebastian B. Lacher2,3,15, ArmanOner1, Yi Sun4,5, Ignazio Piseddu1,6,7, Luisa Fertig1, Sebastijan Spajic1, Stefanie Lesch1,  \nStefanos Michaelides1, Matthias Seifert  1, Adrian Gottschlich 1,8,  \nNatasha Samson1, Lina Majed1, Daria Briukhovetska  1, Donjetë Simnica1, Viktoria Hartmann1, Kathrin Gabriel  1, Sonia Cohen9, Genevieve M. Boland5,9, David Andreu-Sanz1, Emanuele Carlini1, Sophia Stock 1,8,10, Anne Holtermann1,10, Philipp Jie Müller1, ThaddäusStrzalkowski1, Marcel P. Trefny  1, Stefan Endres1,10,11, Russell W. Jenkins 4,5, Jan P. Böttcher2,12,13,16 & Sebastian Kobold 1,10,11,14,16  \nThe efficacy ofchimeric antigen receptor (CAR) T cell therapy in solid cancers is limited by immunosuppression in the tumour microenvironment (TME). Prostaglandin E2 (PGE2) is a key factor locally inhibiting T cell function. We hypothesized that targeted ablationofPGE2 signalling inCART cells may enhance their activity in PGE2-rich solid tumours. Here we generate knockout CART cells double deficient forthePGE2 receptors EP2 and EP4 (EP2−/−EP4−/−) by CRISPR–Cas9 engineering. EP2−/−EP4−/− CART cells expanded unabatedlyin the presence of PGE2. Further, they effectively controlled syngeneic and human xenograft tumour models in vivo, which was accompanied by intratumoural accumulation and persistence of modified T cells. Improved anti-tumour activity was also observed against patient-derived tumour samples from patients with pancreatic ductaladenocarcinoma (PDAC), colorectal (CRC) and neuroendocrine (NET) cancer. Our data uncovers the detrimental impact of PGE2-mediated suppression on CART cell efficacy and highlightsEP2 and EP4 targeting asa potential strategy.  \nChimeric antigen receptor (CAR) T cells have achieved remarkable response rates in otherwise refractory haematologic malignancies and led to the first approval by the US Food and Drug Administration (FDA) in 2017 (ref.1). ACARisa synthetic protein introduced into T cells, which is composed of an extracellular single-chain variable fragment targeting a specific tumour surface antigen, a hinge/spacerand transmembrane domain, an intracellular co-stimulatory domain and an intracellular signalling domain triggering T cell activation2,3.  \nThe advantage of CART cells lies in their ability to merge the specificity of an antibody with the cytotoxic effect of activated T cells ina human leukocyte antigen (HLA)-independent manner2,3. In some patients, a single infusion was sufficient to cure refractory disease4–6. For many years, clinical development has focused on haematological malignancies, but efforts are increasingly expanded to solid tumour entities, such that the clinical trial landscape is growing rapidly7. This development is certainly propelled by the success of immune checkpoint  \nA full list of affiliations appears at the end of the paper. [e-mail:](e-mail: Sebastian.kobold@med.uni-muenchen.de)[ Sebastian.kobold@med.uni-muenchen.de](e-mail: Sebastian.kobold@med.uni-muenchen.de)  \nNature Biomedical Engineering | Volume 10 | April 2026 | 697–710 697  \na  \nC57BL/6 WT (CD90.1)  \nCD4CrePtger2–/–Ptger4􀂅/􀂅  \n(CD45.1)  \nC57BL/6 WT (CD45.2 + CD90.2)  \nb  \nPercentage of CD3+  \n50  \n25  \n0  \nTumour  \nNS \u003C0 .0001 \u003C0 .0001 \u003C0 .0001  \n2 5 9 14 Time (days)  \nc  \nPercentage of CD3+  \n8  \n6  \n4  \n2  \n0  \nLymph nodes  \n\u003C0 .0001 NS NS NS  \n2 5 9 14 Time (days)  \n CD90 .1 OT-I  CD45 .1 ×  \nCD4CrePtger2–/–Ptger4􀂅/􀂅OT-I  \nd  \ncAMP (nM)  \n200  \n150  \n100  \n50  \n0  \n0.0111  \nMock Ep2–/–  \nEp4–/–  \nEp2–/–Ep4–/–  \ne  \npCR EB+(% of CD8+)  \n Vehicle  \n 1,600 ng ml–1 PGE2  \nMock Ep2–/– Ep4–/–","cbCailQnlmNiaIuT","https://ap.wps.com/l/cbCailQnlmNiaIuT","pdf",6896506,26,"English","# Introduction and background\n## Prostaglandin E2 and immunosuppression in the tumour microenvironment\n# Experimental strategy\n## CRISPR–Cas9 engineering of EP2/EP4 double-knockout CAR T cells\n# Results\n## Expansion in PGE2\n## Control of in vivo tumour models and tumour persistence\n## Activity in patient-derived tumour samples\n# Conclusion and implications","[{\"question\":\"Why target prostaglandin E2 signalling in CAR T cells for solid tumours?\",\"answer\":\"PGE2 is highlighted as a key factor locally inhibiting T-cell function, contributing to immunosuppression in the tumour microenvironment.\"},{\"question\":\"How were the CAR T cells modified in this study?\",\"answer\":\"Researchers generated knockout CAR T cells double deficient for the PGE2 receptors EP2 and EP4 using CRISPR–Cas9 engineering (EP2−/−EP4−/−).\"},{\"question\":\"What evidence supports enhanced therapeutic efficacy?\",\"answer\":\"The modified CAR T cells expanded in the presence of PGE2 and effectively controlled syngeneic and human xenograft tumour models in vivo, with improved activity also observed in patient-derived PDAC, CRC, and NET tumour samples.\"}]","Ablation of prostaglandin E2 signalling through dual receptor knockout in CAR T cells enhances therapeutic efficacy in solid tumours | PDF",1790119607,66,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/030329a0b6a3808b10f016c9800f07bb.webp",983,1305,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6f367ea8485fa1a0a80c5d0ff6fa8fb2.webp",982,1304,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9e6ec1940bdcb37d668a0d2e91b37cf9.webp",981,1303,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/036ec712c57d9911a0ecae7e499c172c.webp",980,1301]